36 hours ago Background/aim: Gc protein-derived macrophage-activating factor (GcMAF) has various functions as an immune modulator, such as macrophage activation, anti-angiogenic activity and anti-tumor activity. Clinical trials of second-generation GcMAF demonstrated remarkable clinical effects in several types of cancers. Thus, GcMAF-based immunotherapy has a wide application for use in … >> Go To The Portal
Case report We report a case of a 36-year-old male who developed CNS demyelinating disease, that fulfilled the diagnostic criteria of multiple sclerosis (MS), 2 months after laboratory-confirmed infection with SARS-CoV-2. Conclusion
Full Answer
The purpose of this fictional case study is to highlight key clinical findings in a patient diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS). The patient discussed throughout the case study presents with chronic fatigue, lower extremity weakness, impaired balance, lack of coordination and psychosocial characteristics.
This case study examines a young female patient with a typical presentation of Relapsing Remitting Multiple Sclerosis. The patient sought treatment from physiotherapy after her most recent attack left her with symptoms of fatigue, lower extremity weakness, loss of coordination and balance.
REVIEW OF SYSTEMS is also significant for a number of problems related to her suspected MS. The patient has a tendency to aspirate liquids and also solids. (Q.5) (Q.6) She complains of tinnitus which is continuous and associated with hearing loss, more prominent on the left. She has decreased finger dexterity and weakness of the hands bilaterally.
There are a few different classifications of MS based on occurrence of relapses or progression. The most common form is Relapsing Remitting Multiple Sclerosis (RRMS) whereby the patient will have new symptoms emerge or a worsening of past symptoms, followed by full, or near full recovery .
Multiple sclerosis (MS) is a chronic disease affecting the central nervous system (the brain and spinal cord). MS occurs when the immune system attacks nerve fibers and myelin sheathing (a fatty substance which surrounds/insulates healthy nerve fibers) in the brain and spinal cord.
A total of 2.8 million people are estimated to live with MS worldwide (35.9 per 100,000 population). MS prevalence has increased in every world region since 2013 but gaps in prevalence estimates persist.
Unfortunately, multiple sclerosis (MS) is much more complex and can take months, or even longer, to accurately diagnosis. There is no single test that will tell you if you have MS. Doctors arrive at a diagnosis based on a combination of your symptoms and the results of several different tests.
Those symptoms include loss of vision in an eye, loss of power in an arm or leg or a rising sense of numbness in the legs. Other common symptoms associated with MS include spasms, fatigue, depression, incontinence issues, sexual dysfunction, and walking difficulties.
Rates of MS are higher further from the equator. It's estimated that in southern U.S. states (below the 37th parallel), the rate of MS is between 57 and 78 cases per 100,000 people. The rate is twice as high in northern states (above the 37th parallel), at about 110 to 140 cases per 100,000.
Canada's disease and its place in the world However, MS is also known as “Canada's disease” among health-care professionals because Canada has had, and continues to have, the highest rate of MS in the world.
Here's where MS (typically) starts You may experience eye pain, blurred vision and headache. It often occurs on one side and can eventually lead to partial or total vision loss. Spinal cord inflammation, or what's called partial transverse myelitis, is the second most common symptom Shoemaker typically sees.
Common early signs of multiple sclerosis (MS) include:vision problems.tingling and numbness.pains and spasms.weakness or fatigue.balance problems or dizziness.bladder issues.sexual dysfunction.cognitive problems.
MS can be among the most difficult of all diseases to diagnose because of the bewildering number of symptoms it causes and the multiple ways in which they can present.
What are the 4 stages of MS?Clinically isolated syndrome (CIS) This is the first episode of symptoms caused by inflammation and damage to the myelin covering on nerves in the brain or spinal cord. ... Relapsing-remitting MS (RRMS) ... Secondary-progressive MS (SPMS) ... Primary-progressive MS (PPMS)
Multiple sclerosis is caused by your immune system mistakenly attacking the brain and nerves. It's not clear why this happens but it may be a combination of genetic and environmental factors.
Multiple sclerosis (MS) can cause a wide range of symptoms and affect any part of the body. Each person with the condition is affected differently.fatigue.vision problems.numbness and tingling.muscle spasms, stiffness and weakness.mobility problems.pain.problems with thinking, learning and planning.More items...
Three years later, at 34, Janet awoke to a prickly tingling feeling...
The neurologist made a diagnosis of multiple sclerosis based on the MRI...
Andrea P. Lee, MD; Giulietta M. Riboldi, MD; Ilya Kister, MD; Jonathan E. Howard, MD; and Ritesh A. Ramdhani, MD
Mr L is age 41 with a history of multiple sclerosis (MS), bipolar disorder, and parkinsonism that has persisted despite being off neuroleptics for 1.5 years (Figures 1 and 2).
Multiple sclerosis (MS) is an autoimmune demyelinating disease that commonly causes white matter plaques, but deep grey matter nuclei can also be affected. MS manifests with a wide range of neurologic symptoms depending on the location of lesions. Parkinsonism is rarely comorbid with MS.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) characterized by multiple lesions disseminated in time and space.
A 51-year-old man of Mediterranean origin with an 8-year history of relapsing-remitting MS (RRMS) was admitted to our hospital on suspicion of a relapse.
The rapid clinical deterioration posed a diagnostic challenge. Because of increasing anti-JCV index upon treatment with natalizumab, we speculated that PML might have occurred. However, the MRI findings were atypical (uncommon mass effect and degree of gadolinium enhancement).
In our patient, the results of the brain biopsy finally confirmed the diagnosis of a tumefactive MS lesion. All pathological features of MS were fulfilled including inflammatory demyelination, relative axonal preservation, and gliosis.
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.
Written informed consent was obtained from the individual (s) for the publication of any potentially identifiable images or data included in this article.
KB gave the idea of case reporting, analyzed the case, and drafted the manuscript for intellectual content. AA revised the figures and critically reviewed the manuscript. MF, NG, HH, OA, and H-PH critically reviewed the manuscript. BK prepared the MRI scans as figures and critically reviewed the manuscript.